Kiniksa Pharmaceuticals International, plc (KNSA) Financial Statements (2026 and earlier)

Company Profile

Business Address 105 PICCADILLY, SECOND FLOOR
LONDON, W1J 7NJ
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments414,074243,627206,371190,608182,201323,482
Cash and cash equivalent165,596183,581107,954122,715122,470114,038
Short-term investments248,47860,04698,41767,89359,731209,444
Restricted cash and investments      210
Receivables15,59441,72421,26612,6603,985 
Inventory, net of allowances, customer advances and progress billings54,89526,36431,12221,5993,675 
Inventory54,89526,36431,12221,5993,675 
Contract with customer, asset, after allowance for credit loss    7,656  
Other undisclosed current assets42,61420,08417,53810,5376,5859,557
Total current assets:527,177331,799276,297243,060196,446333,249
Noncurrent Assets
Operating lease, right-of-use asset9,80710,37611,9315,3855,5506,566
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,9436627341,6582,8344,051
Intangible asset, including goodwill, after accumulated amortization15,25016,25017,25018,25019,250 
Intangible asset, excluding goodwill, after accumulated amortization15,25016,25017,25018,25019,250 
Deferred income tax assets198,149211,151219,283185,495 10
Other noncurrent assets11,30710,3158275,8248,7205,588
Total noncurrent assets:236,456248,754250,025216,61236,35416,215
TOTAL ASSETS:763,633580,553526,322459,672232,800349,464
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities44,04834,39452,91338,01139,89929,702
Accounts payable2,0282,0398,2467,8991,868503
Accrued liabilities42,02032,35544,66730,11238,03129,199
Deferred revenue   307   
Other liabilities22,13416,0778,1935,7541,54437
Other undisclosed current liabilities73,00250,1502,2533,3013,3812,107
Total current liabilities:139,184100,62163,66647,06644,82431,846
Noncurrent Liabilities
Long-term debt and lease obligation:     2,6694,878
Liabilities, other than long-term debt56,84341,49623,81716,457270805
Deferred revenue31,81131,81111,95412,000  
Other liabilities18,5221,8231,8581,839270805
Operating lease, liability6,5107,86210,0052,6182,6694,878
Total noncurrent liabilities:56,84341,49623,81716,4572,9395,683
Total liabilities:196,027142,11787,48363,52347,76337,529
Equity
Equity, attributable to parent, including:567,606438,436438,839396,149185,037311,935
Additional paid in capital1,029,748959,722916,763888,120860,482829,424
Accumulated other comprehensive income (loss)(25)(163)644(66)(34)
Accumulated deficit(462,138)(521,143)(477,950)(492,034)(675,397)(517,473)
Other undisclosed equity, attributable to parent212020191818
Total equity:567,606438,436438,839396,149185,037311,935
TOTAL LIABILITIES AND EQUITY:763,633580,553526,322459,672232,800349,464

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues677,564423,239270,259220,18038,544 
Cost of revenue
(Cost of Product and Service Sold)		(77,673)(60,910)  (9,100) 
Gross profit:599,891362,329270,259220,18029,444 
Operating expenses(293,125)(279,634)(205,524)(163,441)(186,080)(157,363)
Other undisclosed operating loss(229,545)(128,311)(89,931)(46,966)  
Operating income (loss):77,221(45,616)(25,196)9,773(156,636)(157,363)
Nonoperating income11,6479,4648,5441,253971,134
Investment income, nonoperating     971,134
Other nonoperating income11,6479,4648,5441,253  
Income (loss) from continuing operations before income taxes:88,868(36,152)(16,652)11,026(156,539)(156,229)
Income tax expense (benefit)(29,863)(7,041)30,736172,337(1,385)(5,152)
Income (loss) from continuing operations:59,005(43,193)14,084183,363(157,924)(161,381)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(157,924)(161,381)
Net income (loss) available to common stockholders, diluted:59,005(43,193)14,084183,363(157,924)(161,381)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):59,005(43,193)14,084183,363(157,924)(161,381)
Comprehensive income (loss):59,005(43,193)14,084183,363(157,924)(161,381)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent138(169)(38)110(32)(67)
Comprehensive income (loss), net of tax, attributable to parent:59,143(43,362)14,046183,473(157,956)(161,448)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: